Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short- versus long-term androgen deprivation therapy with salvage radiotherapy after prostatectomy
2021-006975-41Phase 3Active
- Sponsor
- GICOR
- Start
- Feb 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of triptorelin, leuprolide and goserelin in prostate cancer (PCa) (2 arms), sponsored by GICOR. Primary endpoint: 5-year distant metastasis-free survival. Started Feb 2022; status: active.
02
Drugs
triptorelinleuprolidegoserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2021-006975-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006975-41.